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Abstract 
Review on the group of myeloid/lymphoid 
neoplasms with eosinophilia and rearrangement of 
PDGFRA, PDGFRB, or FGFR1, or with PCM1-
JAK2 defined by the WHO 2016. 
Keywords 
eosinophilia; PDGFRA; PDGFRB; FGFR1, 
PCM1/JAK2 
Clinics and pathology 
Disease 
Eosinophilia is defined as a peripheral blood 
eosinophil count > 0.5x109/L, with > 1.5x109/L of 
eosinophil count sometimes referred to as 
hypereosinophlia. Eosinophilia is a common clinical 
phenotype associated with various conditions 
including allergies, infections, medications, 
autoimmune disorders and malignancies. Although 
malignancy-related eosinophilia is rare, it is an 
important clinical sign of these tumors, which 
require early diagnosis and clinical intervention. 
Figure 1 summaries the initial workup of patients 
with eosinophilia. 
Phenotype/cell stem origin 
WHO 2016 defines a group of myeloid/lymphoid 
neoplasms with eosinophilia and rearrangement of 
PDGFRA, PDGFRB, or FGFR1, or with PCM1 / 
JAK2 as:  
Disease 
(1) Myeloid/lymphoid neoplasms with PDGFRA 
rearrangement 
(2) Myeloid/lymphoid neoplasms with PDGFRB 
rearrangement 
(3) Myeloid/lymphoid neoplasms with FGFR1 
rearrangement 
(4) Provisional entity: Myeloid/lymphoid neoplasms 
with PCM1/JAK2 
Treatment 
This group of patients can be treated with tyrosine 
kinase inhibitors. While patients with PDGFRA or 
PDGFRB rearrangement are highly sensitive to 
Imatinib, PCM1-JAK2 patients had varying 
responses to JAK2 inhibitor Ruxolitinib, which can 
induce complete remission, although the duration is 
often limited. FGFR1 inhibitors have not been very 
successful in treating tumors with FGFR1 
rearrangement. PKC412 was effective in a patient 
with progressive myeloproliferative disorder with 
(8;13) (Chen et al., 2004); however, subsequent 
studies with the FGFR1 inhibitor ponatinib were less 
successful. Novel FGFR1 inhibitors are currently 
being tested in clinical trials for solid tumors with 
FGFR1 activation. Recently a new FGFR family 
kinase inhibitor INCB054828 induced complete 
resolution of eosinophilia as well as complete 
hematologic, cytogenetic and molecular remission in 
a patient with FGFR1 rearranged MPN (Verstovsek 
et al., 2018). 
Myeloid/lymphoid neoplasms with eosinophilia and 
rearrangement of PDGFRA, PDGFRB, or FGFR1, or with 
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Genetics 
The fusion partner genes for PDGFRA, PDGFRB,  
 
or FGFR1 have been steadily accumulating and are 
updated below in Tables. 
 
 
Figure 1.  Testing algorithm for possible haematological neoplasms with clonal eosinophilia. Courtesy of the British Committee 
for Standards in Haematology 
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Gene name Rearrangements 
Detection methods 
Ref (PMID) 
Karyotype FISH RT-PCR NGS 
BCR t(4;22)(q12;q11.2) Yes Yes Yes Yes 15034867 
CDK5RAP2 ins(9;4)(q33;q12q25) Yes Yes Yes Yes 16845659 
ETV6 t(4;12)(q12;p13) Yes Yes Yes Yes 17555450 
FIP1L1 del(4)(q12q12) No Yes Yes Yes 12660384 
FOXP1 t(3;4)(p13;q12) Yes Yes Yes Yes 26319757 
KIF5B t(4;10)(q12;p11) Yes Yes Yes Yes 16498388 
STRN t(2;4)(p24;q12) Yes Yes Yes Yes 17555450 
TNKS2 t(4;10)(q12;q23.3) Yes Yes Yes Yes 25658984 
Table 1: PDGFRA fusion partners, chromosome locations, detection methods and references 
 
Gene name Rearrangements 
Detection methods 
Ref (PMID) 
Karyotype FISH RT-PCR NGS 
AGGF1 add(5) Yes Yes Yes Yes 
28552906; 
29284681 
ATF7IP t(5;12)(q33;p13) Yes Yes Yes Yes 24628626 
BIN2 t(5;12)(q32;q13) Yes Yes Yes Yes 20085582 
CAPRIN1 t(5;11)(q33;p13) Yes Yes Yes Yes 17296564 
CCDC6 t(5;10)(q33;q21) Yes Yes Yes Yes 10910073 
CCDC88C t(5;14)(q33;q32) Yes Yes Yes Yes 15496975; 24772479 
CEP85L t(5;6)(q33-34;q23) Yes Yes Yes Yes 21938754 
CPSF6 t(5;12)(q33;q15) Yes Yes Yes Yes 26355392 
DIAPH1 t(5;5)(q31.3;q32) No Yes Yes Yes 28751768 
DOCK2 del(5) No Yes Yes Yes 28552906 
DTD1  t(5;20)(q33;p11) Yes Yes Yes Yes 24772479 
EBF1 del(5)(q32q33) No Yes Yes Yes 23835704 
ERC1 t(5;12)(q33;p13) Yes Yes Yes Yes 17690697 
ETV6 t(5;12)(q33;p13) Yes Yes Yes Yes 8168137 
GCC2 t(2;5)(q37;q31) Yes Yes Yes Yes 30697976 
GIT2  t(5;12)(q33;q24) Yes Yes Yes Yes 17296564 
GOLGA4  t(3;5)(p22;q31) Yes Yes Yes Yes 20085582 
GOLGB1  t(3;5)(q13;q32) Yes Yes Yes Yes 26355392 
HIP1 t(5;7)(q33;q11) No Yes Yes Yes 9616134 
KANK1 t(5;9)(q32;p24) Yes Yes Yes Yes 20164854 
MPRIP t(5;17)(q32;p11) Yes Yes Yes Yes 26355392 
MYO18A t(5;17)(q32;q11) Yes Yes Yes Yes 28261327 
NDE1 t(5;16)(q32;p13) Yes Yes Yes Yes 17301821 
NIN t(5;14)(q33;q24) Yes Yes Yes Yes 15087377 
NUMA1 t(5;11) (q32;q13.4) Yes Yes Yes Yes 28449810 
PCM1 ins(8;5)(p23;q33q35) Yes Yes Yes Yes 29169164 
PRKG2 t(4;5)(q21;q33) Yes Yes Yes Yes 18262053 
RABEP1 t(5;17)(q33;p13) Yes Yes Yes Yes 11588050 
SART3 t(5;12)(q32;q23) Yes Yes Yes Yes 20107158 
SATB1 t(3;5)(p24;q32) Yes Yes Yes Yes 28552906 
SPECC1 t(5;17)(q33;p11.2) Yes Yes Yes Yes 15087372 
SPTBN1 t(2;5)(p21;q33) Yes Yes Yes Yes 18262053 
TBL1XR1 (3;5)(q26;q32) Yes Yes Yes Yes 28509585 
TNIP1 t(5;5)(q32;q33) No Yes Yes Yes 28408464 
Myeloid/lymphoid neoplasms with eosinophilia and 
rearrangement of PDGFRA, PDGFRB, or FGFR1, or with 
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TP53BP1 t(5;15)(q33;q22) Yes Yes Yes Yes 15492236 
TPM3 t(1;5)(q21;q32) Yes Yes Yes Yes 16838028 
TRIP11 t(5;14)(q33;q32) Yes Yes Yes Yes 9373237 
TSC1 t(5;9)(q32;q34) Yes Yes Yes Yes 29384404 
WDR48 t(1;3;5)(p36;p21;q33)  Yes Yes Yes Yes 20085582 
ZMYND8  t(5;20)(q32;q13) Yes Yes Yes Yes 28408464 
Table 2:  PDGFRB fusion partners, chromosome locations, detection methods and references 
 
Gene name Rearrangements 
Detection methods 
Ref (PMID) 
Karyotype FISH RT-PCR NGS 
BCR t(8;22)(p11;q11) Yes Yes Yes Yes 
11746971; 
11739186 
CNTRL t(8;9)(p12;q33) Yes Yes Yes Yes 10688839 
CPSF6 t(8;12)(p11;q15) Yes Yes Yes Yes 18205209 
CUX1 t(7;8)(q22;p11) Yes Yes Yes Yes 21330321 




Yes Yes Yes Yes 15034873 
ERVK-6 t(8;19)(p12;q13) Yes Yes Yes Yes 12393597 
Table 3: FGFR1 fusion partners, chromosome locations, detection methods and references 
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